Rapamycin, a key modulator of the mammalian Target of Rapamycin (mTOR) pathway has shown neuroprotection properties in several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease and spinocerebellar ataxia type 3 [71, 72, 85]. This evidence concerns the gene MTOR and early-onset autosomal dominant Alzheimer disease.